Departments of Medicine and Anaesthesia, Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Lancet Respir Med. 2014 Dec;2(12):1016-26. doi: 10.1016/S2213-2600(14)70217-6. Epub 2014 Oct 28.
Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.
多能间充质干细胞（基质）在急性呼吸窘迫综合征（ARDS）和脓毒症的临床前模型中显示出有希望的治疗效果。尽管最初的研究集中在间充质干细胞在组织损伤部位植入的能力上，但越来越多的证据表明，间充质干细胞通过与长期纳入宿主组织无关的机制发挥其治疗作用。其中最引人注目的途径之一是间充质干细胞通过释放可溶性生物活性因子与受损组织相互作用的能力。这篇综述概述了间充质干细胞的一般特性，然后概述了间充质干细胞的旁分泌作用如何减轻 ARDS 和脓毒症中的肺损伤并增强肺修复。最后，我们总结了间充质干细胞研究中存在的挑战，并确定了该学科在未来几年可能取得进展的领域。
